Skip to main content

Table 2 NNS use during the first 21 full days of treatment; data from 1050 days of observation from 50 patients.*

From: Use of nicotine substitute prescribed at hourly plus ad libitum intake or ad libitum for heavy smokers willing to quit: a randomized controlled trial

 

NNS

1 dose per hour

NNS

Ad libitum

Wald Chi2 test

ICC

 

Mean (CI 95%)

Mean (CI 95%)

p-value

ρ

Doses

    

   Daily number of intakes

13.6 (4.7; 22.6)

11.1 (7.3; 14.8)

p = 0.332

ρ = 0.606

   Daily number of correct doses (2 puffs)

12.0 (3.9; 20.2)

9.3 (5.9; 12.7)

p = 0.263

ρ = 0.593

   Daily number of single puff

0.5 (-0.4; 1.5)

0.8 (0.4; 1.2)

p = 0.470

ρ = 0.414

   Daily number of doses over 2 puffs

1.1 (-0.1; 2.2)

1.0 (0.5;1.4)

p = 0.780

ρ = 0.331

Period of use

    

   Daily intake 1st week

13.7 (3.6; 23.8)

12.9 (8.7; 17.1)

p = 0.788

ρ = 0.798

   Daily intake 2nd week

14.5 (4.4;24.6)

10.5 (6.3; 14.7)

p = 0.184

ρ = 0.696

   Daily intake 3rd week

12.8 (5.6; 22.2)

9.8 (5.8;13.7)

p = 0.287

ρ = 0.656

Week days

    

   Daily intake weekends

13.2 (4.3; 22.2)

9.7 (6.0;13.4)

p = 0.189

ρ = 0.525

   Daily intake weekdays

13.8 (4.5; 23.1)

11.6 (7.7; 15.4)

p = 0.419

ρ = 0.652

Use of NNS

    

   Days NNS was used

22.9 (19.0; 27.3)

23.0 (18.8;27.3)

p = 0.966

-

   Total nicotine (mg)

418 (294; 543)

296 (188; 405)

p = 0.131

-

  1. * Results are drawn from random-effect GLS regression taking lack of independence from measurements from the same patients into consideration.
  2. Individual level data was used for this analysis. T-test was used to calculate p-value.
  3. ‡ The Intraclass Correlation Coefficient (ρ) corresponds to the percentage of variance due to individual characteristics (cluster level).